ClinicalTrials.gg
CompletedNCT06956495UnitasUpdated Oct 22, 2025

Efficacy and Tolerability of Tasipimidine in Sleepless Patients

A Phase 2 interventional study of Tasipimidine and Tasipimidine placebo in Insomnia, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2023, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland — 3 open to participants now, 4 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Finland.

Enrollment
11th of 16
190 · median 367
Started
2023
with 1 other
Phase 2
Only one
of the 16
Registered
16th of 16
by date
Lead sponsor
1 of 16
Orion Corporation, Orion Pharma

Among the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland, this one is the 11th largest by enrollment, is one of 2 that started in 2023, is the only one in phase 2, and was the 16th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 734 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

3 of the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 60 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland, or all of them as a file.
02

Study summary

The goal of this trial is to learn if tasipimidine will help in the treatment of insomnia and how safe it is to use in sleepless people. Researchers will compare tasipimidine to a placebo (a look-alike substance that contains no drug) to see if tasipimidine works to treat insomnia. The trial consists of 2 consecutive parts and participants will be included either in Part 1 or Part 2. Part 2 will start only after Part 1 completion. Both parts include a screening period (up to 6 weeks), a treatment period (3 consecutive days and nights) and a post-treatment period (up to 10 days). Part 2 includes an additional 4 week extension part, where the participants take tasipimidine or placebo every evening at home and return to the sleep clinic for 2 last treatment nights. Participants will use equipment to record sleep parameters both at sleep clinic and home (Part 2) and a sleep diary is used.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed (IC) for participation in the study.
  • Male or female subjects with age between 18 and 65 years.
  • Insomnia disorder
  • Self-reported history of the following on at least 3 nights per week and for at least 3 months prior to the screening: ≥ 30 minutes to fall asleep, subjective total sleep time ≤ 6 hours.
  • Insomnia Severity Index© (ISI©) score ≥ 15 in Part 1 and ≥ 11 in Part 2.
  • Usual bedtime between 21:00 and 02:00.
  • Regular time in bed between 6 and 9 hours.
  • Meeting predefined sleep parameter criteria in sleep recording on the 2 screening nights.
  • Highly effective .

Exclusion criteria

Exclusion Criteria:

  • below 18.5 or above 40.0 kg/m2.
  • Daytime napping ≥ 1 hour per day, and ≥ 3 days per week.
  • Shift work within 2 weeks prior to the screening visit, or planned shift work during the study.
  • Travel across ≥ 3 time zones within 2 weeks prior to the screening visit, or planned travel across ≥ 3 time zones during the study.
  • Use of certain medications affecting central nervous system, e.g. sedatives or stimulans.
  • Start of other new chronic medication within 14 days prior screening nights and planned change to an ongoing chronic medication during the study.
  • Cognitive behavioural therapy (CBT) is allowed if the CBT started at least 1 month prior to the 1st screening night and the subject agreed to continue the CBT throughout the study.
  • Diagnosed sleep-related breathing disorder, including and sleep apnoea.
  • Acute or unstable psychiatric conditions.
  • Alcohol or substance use disorder within 2 years prior to the screening visit or inability to refrain from drinking alcohol for at least 3 consecutive days.
  • Significant cardiac disease.
  • Significant postural hypotension.
  • Heavy tobacco or other nicotine containing product use.
  • Caffeine consumption ≥ 600 mg per day or regular caffeine consumption after 4 p.m.
  • Heart rate \< 50 bpm or > 100 bpm.
  • Systolic blood pressure \< 100 or > 160 mmHg or diastolic blood pressure \< 50 or > 100 mmHg
  • Abnormal 12-lead finding.
  • Significant abnormal laboratory findings including positive drug screen and presence of alcohol in breath test.
  • Pre-planned elective surgery.
  • Pregnant or lactating females.
  • Blood donation or loss of significant amount of blood prior to the study.
  • Participation in a drug study within 60 days prior to the study.
  • Restless legs syndrome, circadian rhythm disorder, REM behaviour disorder, or narcolepsy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Tasipimidine Dose level 1

    Dose level 1

    Drug: Tasipimidine

  • Experimental
    Tasipimidine Dose level 2

    Dose level 2

    Drug: Tasipimidine

  • Experimental
    Tasipimidine Dose level 3

    Dose level 3

    Drug: Tasipimidine

  • Placebo comparator
    Placebo

    Tasipimidine Placebo

    Drug: Tasipimidine placebo

  • Experimental
    Tasipimidine Dose level 4

    Dose level 4

    Drug: Tasipimidine

Interventions

  • DrugTasipimidine

    Tasipimidine solution

    Also known as: ODM-105

  • DrugTasipimidine placebo

    Tasipimidine placebo solution

    Also known as: ODM-105 placebo

06

What researchers measure

Primary outcomes

  1. Wake after sleep onset (WASO) combined from Part 1 and Part 2

    Assessed with polysomnography (PSG) for Day 1 and Day 2 data combined from Part 1 and Part 2

    Time frame: Treatment Day 1 and 2

  2. Latency to persistent sleep (LPS) combined from Part 1 and Part 2

    Assessed with polysomnography (PSG) for Day 1 and Day 2 data combined from Part 1 and Part 2

    Time frame: Treatment Day 1 and 2

07

Study locations

1 site
  • Terveystalo Helsinki Uniklinikka
    Helsinki, 00380, Finland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Sep 2025, 24 months.

Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 24 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 4, 2025
StartActual
Aug 20, 2023
Primary completionActual
Sep 11, 2025
CompletionActual
Sep 24, 2025
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956495
Collaborators
ICON Clinical Research
Responsible party
Sponsor
First posted
May 4, 2025
Start date
Aug 20, 2023
Primary completion
Sep 11, 2025
Completion
Sep 24, 2025
Last update
Oct 22, 2025

Study contacts

Clinical Study Director
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion